Products

NS Pharma is working to develop products for patients with rare diseases. We aspire to offer innovative pharmaceutical therapies to people with unmet medical need to potentially extend and improve quality of life.

Our products

NS Pharma, Inc. has been developing products to change
the way patients and doctors fight rare diseases.

VILTEPSO® (viltolarsen), an exon-skipping therapy designed for patients with Duchenne muscular dystrophy (DMD), was granted accelerated approval by the FDA. Preliminary results from a Phase 3 confirmatory study of VILTEPSO have been received and are undergoing analysis and discussion with the FDA.

View indication and ISI

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.

Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

For more information about VILTEPSO, see full Prescribing Information.

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

News / February 7, 2025

The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs

Press Release / January 27, 2025

Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

News / February 7, 2025

The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs

Press Release / January 27, 2025

Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.